"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 4 | 0 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 4 | 0 | 4 |
| 2013 | 5 | 0 | 5 |
| 2014 | 5 | 0 | 5 |
| 2015 | 8 | 0 | 8 |
| 2016 | 9 | 0 | 9 |
| 2017 | 5 | 0 | 5 |
| 2018 | 8 | 0 | 8 |
| 2019 | 10 | 0 | 10 |
| 2020 | 11 | 1 | 12 |
| 2021 | 9 | 1 | 10 |
| 2022 | 12 | 0 | 12 |
| 2023 | 5 | 0 | 5 |
| 2024 | 8 | 1 | 9 |
| 2025 | 4 | 0 | 4 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
FcRH5?CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med. 2026 Aug; 32(8):2909-2917.
-
Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia. Leuk Lymphoma. 2026 Apr; 67(5):989-996.
-
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr?m macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.
-
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet. 2025 Jul; 57(7):1695-1707.
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
-
Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review. Cancer. 2025 May 15; 131(10):e35896.
-
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
-
Ophthalmoplegia Associated With Extramedullary Multiple Myeloma: Case Series From a Tertiary Cancer Center. J Neuroophthalmol. 2024 12 01; 44(4):533-539.
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 12; 65(12):1789-1800.
-
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024 Oct 01; 30(19):4482-4490.